Publications

Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Targeting CDK2 in cancer: challenges and opportunities for therapy

Abstract

Cyclin-dependent kinase 2 (CDK2) plays a pivotal part in cell cycle regulation and is involved in a range of biological processes. CDK2 interacts with and phosphorylates proteins in pathways such as DNA damage, intracellular transport, protein degradation, signal transduction, DNA and RNA metabolism and translation. CDK2 and its regulatory subunits are deregulated in many human cancers and there is emerging evidence suggesting CDK2 inhibition elicits antitumor activity in a subset of tumors with defined genetic features. Previous CDK2 inhibitors were nonspecific and limited by off-target effects. The development of new-generation CDK2 inhibitors represents a therapeutic opportunity for CDK2-dependent cancers.

Type Journal
ISBN 1878-5832 (Electronic) 1359-6446 (Linking)
Authors Tadesse, S.; Anshabo, A. T.; Portman, N.; Lim, E.; Tilley, W.; Caldon, C. E.; Wang, S.
Responsible Garvan Author Dr Liz Caldon
Publisher Name DRUG DISCOVERY TODAY
Published Date 2020-02-01
Published Volume 25
Published Issue 2
Published Pages 406-413
Status Published in-print
DOI 10.1016/j.drudis.2019.12.001
URL link to publisher's version https://www.ncbi.nlm.nih.gov/pubmed/31839441